{"name":"TARGET","title":"","children":[{"id":"AHR","name":"AHR","presenterLast":"AHR","children":[{"id":3150,"name":3150,"title":"Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo","presenterFirst":"Fred","presenterLast":"Aswad","keywords":"Aryl hydrocarbon receptor;Immunomodulation;Small molecule inhibitor;Drug discovery","target":"AHR","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":10832,"name":10832,"title":"The aryl hydrocarbon receptor as driver of cancer immunity","presenterFirst":"David","presenterLast":"Sherr","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Oral Cancer;Cancer immunotherapy","target":"AHR","tumor":"melanoma_headneck_breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"arginase1","name":"arginase1","presenterLast":"arginase1","children":[{"id":6200,"name":6200,"title":"High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy","presenterFirst":"Yvonne","presenterLast":"Grobben","keywords":"Immunotherapy;Structure-based drug design;High throughput assay;Arginase","target":"arginase1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":10805,"name":10805,"title":"Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors","presenterFirst":"Humberto","presenterLast":"Lara-Guerra","keywords":"Arginine deprivation;Solid tumors;pegzilarginase","target":"arginase1","tumor":"multiple","sage":"target-tumor","pharma":"academia","combo":"no","model":"clinical"}]},{"id":"Cathepsin","name":"Cathepsin","presenterLast":"Cathepsin","children":[{"id":875,"name":875,"title":"Small-molecule inhibition of cathepsins L and K as potential therapeutics for macrophage-driven breast cancer","presenterFirst":"Samantha","presenterLast":"Dykes","keywords":"Breast cancer;Macrophages;Cathepsin L;Invasion","target":"Cathepsin","tumor":"breast","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"CCL16","name":"CCL16","presenterLast":"CCL16","children":[{"id":3197,"name":3197,"title":"The biological significance of CCL 16 regulated by thyroid hormone in liver cancer cells","presenterFirst":"Cheng-Heng","presenterLast":"Wu","keywords":"Hepatocellular carcinoma;Chemokines;Macrophages;Thyroid Hormone","target":"CCL16","tumor":"hcc","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"CCL5","name":"CCL5","presenterLast":"CCL5","children":[{"id":2758,"name":2758,"title":"Targeting autophagy inhibits B16-F10 melanoma growth by enhancing the infiltration of functional NK cells in a CCL5-dependent manner","presenterFirst":"Bassam","presenterLast":"Janji","keywords":"Autophagy;Chemokines;melanoma;Natural killer cells","target":"CCL5","tumor":"melanoma","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"CD137","name":"CD137","presenterLast":"CD137","children":[{"id":7006,"name":7006,"title":"Small synthetic, multivalent bicyclic peptides that activate T cell costimulatory protein CD137","presenterFirst":"Peter","presenterLast":"Park","keywords":"Immunotherapy;Co-stimulation;Cancer therapy;Targeted therapy","target":"CD137","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"CD39_CD73","name":"CD39_CD73","presenterLast":"CD39_CD73","children":[{"id":2629,"name":2629,"title":"Monitoring CD73 and CD39 ectonucleotidase activities and their modulation by antibodies and small molecules inhibitors","presenterFirst":"Said","presenterLast":"Goueli","keywords":"Cancer marker;Signaling pathways;Hypoxia-inducible genes;Small molecule inhibitor","target":"CD39_CD73","tumor":"NA","sage":"discovery","pharma":"academia","combo":"no","model":"in silico"}]},{"id":"CSF1-R","name":"CSF1-R","presenterLast":"CSF1-R","children":[{"id":3241,"name":3241,"title":"Preclinical evaluation of the multi tyrosine kinase inhibitor TAS-115 in genetically engineered mouse models of prostate cancer","presenterFirst":"Hirotsugu","presenterLast":"Uemura","keywords":"Kinase inhibitors;Targeted therapy;Prostate cancer;Preclinical testing","target":"CSF1-R","tumor":"prostate","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3732,"name":3732,"title":"NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML","presenterFirst":"Marina","presenterLast":"Ciomei","keywords":"Leukemias: acute myeloid;FLT3;CSF-1R;NMS-P088","target":"CSF1-R","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":10771,"name":10771,"title":"Promoting an anti-tumor immune environment with a novel, exquisitely selective CSF1R inhibitor","presenterFirst":"Joseph","presenterLast":"Marszalek","keywords":"Macrophages;Drug discovery;CSF1R","target":"CSF1-R","tumor":"colorectal_pancreatic","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"CX3CR1","name":"CX3CR1","presenterLast":"CX3CR1","children":[{"id":5044,"name":5044,"title":"The CX3CR1-Fractalkine axis drives both circulating prostate cancer cells and macrophages to the bone metastatic microenvironment","presenterFirst":"Ramanpreet","presenterLast":"Kaur","keywords":"Prostate cancer;Microenvironment;Chemokine receptor;Macrophages","target":"CX3CR1","tumor":"prostate","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"CXCL12","name":"CXCL12","presenterLast":"CXCL12","children":[{"id":7868,"name":7868,"title":"Cxcl-12-cxcr4 inhibition enhances immune response in pancreatic ductal adenocarcinoma","presenterFirst":"Bharti","presenterLast":"Garg","keywords":"T cell;Stroma;Cancer;Immune response","target":"CXCL12","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"CXCR1/2","name":"CXCR1/2","presenterLast":"CXCR1/2","children":[{"id":2853,"name":2853,"title":"Therapy-induced senescence associated secretory phenotype enhances breast cancer cell invasion and stemness via CXCR1/2-CXCR1/2 ligands axis","presenterFirst":"Yong Won","presenterLast":"Choi","keywords":"Senescence;Interleukin-8;Breast cancer","target":"CXCR1/2","tumor":"breast","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"CXCR2","name":"CXCR2","presenterLast":"CXCR2","children":[{"id":3049,"name":3049,"title":"CXCR2 signaling in pancreatic cancer induces a tumor supporting inflammatory phenotype of the cancer-associated fibroblasts","presenterFirst":"Mohammad","presenterLast":"Awaji","keywords":"Chemokines;Cancer associated fibroblasts","target":"CXCR2","tumor":"pancreatic","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"},{"id":9307,"name":9307,"title":"The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model","presenterFirst":"Wen-Hai","presenterLast":"Huang","keywords":"Drug discovery;Pharmacophore;CXCR2;antagonists","target":"CXCR2","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"in silico"}]},{"id":"CXCR4","name":"CXCR4","presenterLast":"CXCR4","children":[{"id":5296,"name":5296,"title":"Obesity and prostate cancer progression: Role of the chemokine CXCL12","presenterFirst":"Songyeon","presenterLast":"Ahn","keywords":"Obesity;Prostate cancer;CXCL12;CXCR4/CXCR7","target":"CXCR4","tumor":"prostate","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":6279,"name":6279,"title":"Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells","presenterFirst":"Nobuyuki","presenterLast":"Kuribayashi","keywords":"CXCR4;Metastasis;Oral Cancer","target":"CXCR4","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"CXCR7","name":"CXCR7","presenterLast":"CXCR7","children":[{"id":3152,"name":3152,"title":"CXCR7 promotes the migration and invasion of head and neck squamous cell carcinoma through Smad2/Akt signaling","presenterFirst":"Nayoung","presenterLast":"Kim","keywords":"Chemokine receptor;CXCR7;Epithelial-to-mesenchymal transition","target":"CXCR7","tumor":"headneck","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"ENPP1","name":"ENPP1","presenterLast":"ENPP1","children":[{"id":8167,"name":8167,"title":"Discovery of ENPP1 inhibitors as agonists of STING pathway","presenterFirst":"Sunil","presenterLast":"Sharma","keywords":"Immunomodulation;Therapeutics;Small molecule inhibitor;Cancer immunotherapy","target":"ENPP1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"Eselectin_CXCR4","name":"Eselectin_CXCR4","presenterLast":"Eselectin_CXCR4","children":[{"id":5435,"name":5435,"title":"Mobilization of tumor-primed, marrow-infiltrating lymphocytes into peripheral blood with inhibitors of E-selectin or E-selectin and CXCR4","presenterFirst":"William","presenterLast":"Fogler","keywords":"E-selectin;CXCR4;T lymphocytes;Bone marrow","target":"Eselectin_CXCR4","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"Foxp3","name":"Foxp3","presenterLast":"Foxp3","children":[{"id":2858,"name":2858,"title":"High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models","presenterFirst":"Charles","presenterLast":"Sinclair","keywords":"Regulatory T cells;Foxp3;Antisense oligonucleotides","target":"Foxp3","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"glutamine","name":"glutamine","presenterLast":"glutamine","children":[{"id":5324,"name":5324,"title":"Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation and function of suppressive myeloid cells","presenterFirst":"Min-Hee","presenterLast":"Oh","keywords":"Tumor microenvironment;Innate immunity;Metastatic tumors;Metabolism","target":"glutamine","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"HDAC11","name":"HDAC11","presenterLast":"HDAC11","children":[{"id":2933,"name":2933,"title":"HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition","presenterFirst":"Jie","presenterLast":"Chen","keywords":"Histone deacetylase;MDSCs;C/EBPbeta","target":"HDAC11","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"HSP90","name":"HSP90","presenterLast":"HSP90","children":[{"id":4840,"name":4840,"title":"Transcriptomics analysis of SNX-2112 on immune and mitochodrial genes","presenterFirst":"Everardus","presenterLast":"Orlemans","keywords":"Immune response;SNX-2112;epigenetic Hsp90 inhibitor;oncometabolism","target":"HSP90","tumor":"melanoma_leukemia","sage":"discovery","pharma":"pharma","combo":"no","model":"in silico"}]},{"id":"IDO1","name":"IDO1","presenterLast":"IDO1","children":[{"id":2017,"name":2017,"title":"Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers","presenterFirst":"Shoujun","presenterLast":"Chen","keywords":"Immunotherapy;IDO1 inhibitor;Immuno-oncology;PD-1 inhibitor","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":4503,"name":4503,"title":"Impact of IDO inhibitor on tryptophan and kynurenine pathway reflected in the tumor microenvironment and highlighted using quantitative mass spectrometry imaging","presenterFirst":"Lauranne","presenterLast":"Poncelet","keywords":"Mass spectrometry;Mass spectrometry;Drug delivery","target":"IDO1","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5745,"name":5745,"title":"Preclinical evaluation of TQBWX220, a small-molecule inhibitor of IDO1","presenterFirst":"Shilan","presenterLast":"Liu","keywords":"Immunotherapy;Tumor immunity;Tumor microenvironment;IDO1 inhibitor","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":10677,"name":10677,"title":"Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model","presenterFirst":"Alessia","presenterLast":"Petrocchi","keywords":"Drug discovery;IDO1 inhibitors","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"IDO1_IDO2","name":"IDO1_IDO2","presenterLast":"IDO1_IDO2","children":[{"id":5335,"name":5335,"title":"Indoximod modulates AhR-driven transcription of genes that control immune function","presenterFirst":"Erik","presenterLast":"Brincks","keywords":"Immunotherapy;Aryl hydrocarbon receptor;Immunomodulation","target":"IDO1_IDO2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"IDO1_IDO2_TDO","name":"IDO1_IDO2_TDO","presenterLast":"IDO1_IDO2_TDO","children":[{"id":5329,"name":5329,"title":"Targeting the kynurenine pathway as a novel metabolic treatment for head and neck cancer","presenterFirst":"Chitra","presenterLast":"Subramanian","keywords":"Head and neck squamous cell carcinoma;IDO1;glycolysis;Kynurenine","target":"IDO1_IDO2_TDO","tumor":"headneck","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"IDO1_KYN","name":"IDO1_KYN","presenterLast":"IDO1_KYN","children":[{"id":609,"name":609,"title":"Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer","presenterFirst":"Medhi","presenterLast":"Wangpaichitr","keywords":"Lung cancer;Cisplatin resistance;Metabolism","target":"IDO1_KYN","tumor":"lung","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"KIT_SCF","name":"KIT_SCF","presenterLast":"KIT_SCF","children":[{"id":5395,"name":5395,"title":"Kit-dependent tissue resident macrophage progenitors drive cancer progression","presenterFirst":"Paulina","presenterLast":"Pathria","keywords":"Macrophages;Inflammation;Kit tyrosine kinase;Stem cells","target":"KIT_SCF","tumor":"NA","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"MEK","name":"MEK","presenterLast":"MEK","children":[{"id":7149,"name":7149,"title":"High-throughput analysis of MAPK and JAK-STAT signaling in CT26 tumors using a combination of immunophenotyping and phospho-flow cytometry","presenterFirst":"Scott","presenterLast":"Wise","keywords":"Flow cytometry;Phosphorylation;Immunomodulation","target":"MEK","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"MNK1/2","name":"MNK1/2","presenterLast":"MNK1/2","children":[{"id":5676,"name":5676,"title":"eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response","presenterFirst":"Rajesh","presenterLast":"Sharma","keywords":"Immunotherapy;MNK1/2;T cell differentiation;Antitumor activity","target":"MNK1/2","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5685,"name":5685,"title":"Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response","presenterFirst":"Craig","presenterLast":"Stumpf","keywords":"Immunomodulation;T cell;MNK;eFT508","target":"MNK1/2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"p160SRC","name":"p160SRC","presenterLast":"p160SRC","children":[{"id":7958,"name":7958,"title":"A highly potent novel class of SRC-3 inhibitors for the treatment of uveal melanoma","presenterFirst":"Salma","presenterLast":"Kaochar","keywords":"Melanoma/skin cancers;Uveal Melanoma;SRC-3;GNAQ mutant","target":"p160SRC","tumor":"melanoma","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"PD1/L1","name":"PD1/L1","presenterLast":"PD1/L1","children":[{"id":2992,"name":2992,"title":"Rational design of small-molecule immune checkpoints' inhibitors","presenterFirst":"Khaled","presenterLast":"Barakat","keywords":"Cancer;Immunomodulation;Cancer immunotherapy;Immune response","target":"PD1/L1","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"NA"},{"id":3537,"name":3537,"title":"Interference of PD-1 and PD-L1 interaction with small-molecule inhibitors enhances the efficacy of tumor-specific CTLs","presenterFirst":"Priscilla","presenterLast":"Redd","keywords":"Cytotoxic T lymphocytes;Small molecule inhibitor;Immunotherapy;PD-L1","target":"PD1/L1","tumor":"breast","sage":"drug","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3699,"name":3699,"title":"Novel, heterocyclic small molecule inhibitors of PD-1 and PD-L1 pathway","presenterFirst":"Sivanandhan","presenterLast":"Dhanalakshmi","keywords":"Immunomodulation;Small molecule inhibitor","target":"PD1/L1","tumor":"renal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":7627,"name":7627,"title":"The rational design and evaluation of a peptide inhibitor of the PD-1/PD-L1 interaction","presenterFirst":"Rebecca","presenterLast":"Boohaker","keywords":"Immunomodulation;T cell;T lymphocytes;Drug design","target":"PD1/L1","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"PEDF","name":"PEDF","presenterLast":"PEDF","children":[{"id":7220,"name":7220,"title":"Reprogramming of tumor-associated macrophages by a short synthetic peptide eradicates ovarian cancer","presenterFirst":"Reshma","presenterLast":"Bhowmick","keywords":"Macrophages;Gynecological cancers: ovarian;Microenvironment;Innate immunity","target":"PEDF","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"PGE2","name":"PGE2","presenterLast":"PGE2","children":[{"id":4521,"name":4521,"title":"Myeloid-derived suppressor cells potentiate colorectal carcinogenesis: Identification of a novel RIPK3-PGE2 circuit in tumor microenvironment","presenterFirst":"Yongsheng","presenterLast":"Li","keywords":"Gastrointestinal cancers: colorectal;Prostaglandin E2;NF-[kappa]B;Cyclooxygenase","target":"PGE2","tumor":"colorectal","sage":"discovery","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"PI3Kg","name":"PI3Kg","presenterLast":"PI3Kg","children":[{"id":6224,"name":6224,"title":"The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment","presenterFirst":"Stefania","presenterLast":"Capano","keywords":"PI3K;Macrophages","target":"PI3Kg","tumor":"breast_colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"SATA3","name":"SATA3","presenterLast":"SATA3","children":[{"id":3135,"name":3135,"title":"Novel nano-molar small-molecule STAT3 inhibitor series with antitumor activities against human breast cancer","presenterFirst":"Peibin","presenterLast":"Yue","keywords":"STAT3;Small molecule inhibitor;Breast cancer;Antitumor agents","target":"SATA3","tumor":"breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"STING","name":"STING","presenterLast":"STING","children":[{"id":4151,"name":4151,"title":"Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity","presenterFirst":"Jingsong","presenterLast":"Yang","keywords":"Cancer immunotherapy;Immunostimulation;Antigen presentation;Interferons","target":"STING","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6327,"name":6327,"title":"Endogenous STING inhibition induces breast cancer cell death","presenterFirst":"Hery","presenterLast":"Ratsima","keywords":"Breast cancer;Drug resistance;DNA damage;Immunotherapy","target":"STING","tumor":"breast","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6738,"name":6738,"title":"Identification and optimization of chemical compounds as potent agonists of human STING with anticancer activity in mice","presenterFirst":"Jian Hui","presenterLast":"Wu","keywords":"Small molecule drugs;STING Agonist;Prostate cancer","target":"STING","tumor":"NA","sage":"drug","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"TAM","name":"TAM","presenterLast":"TAM","children":[{"id":7410,"name":7410,"title":"Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development","presenterFirst":"Amanda","presenterLast":"Albert","keywords":"Immunomodulation;Innate immunity;Tyrosine kinase inhibitor;Macrophages","target":"TAM","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"TDO2","name":"TDO2","presenterLast":"TDO2","children":[{"id":1982,"name":1982,"title":"Tryptophan catabolism in ovarian cancer","presenterFirst":"Lynelle","presenterLast":"Smith","keywords":"Gynecological cancers: ovarian;Ovarian cancer - serous;Tumor immunity;Immunomodulation","target":"TDO2","tumor":"ovarian","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical in vitro"}]},{"id":"TLR7","name":"TLR7","presenterLast":"TLR7","children":[{"id":881,"name":881,"title":"Protumoral and pro-metastatic effects of TLR7 in lung cancer","presenterFirst":"Isabelle","presenterLast":"Cremer","keywords":"Tumor microenvironment;TLR7;pro-tumoral;resistance to chemotherapy","target":"TLR7","tumor":"lung","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"TLR7/8","name":"TLR7/8","presenterLast":"TLR7/8","children":[{"id":3077,"name":3077,"title":"NKTR-262: Prodrug pharmacokinetics in mice, rats, and dogs","presenterFirst":"Myong","presenterLast":"Lee","keywords":"Immunotherapy","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":3142,"name":3142,"title":"Synergistic immunotherapeutic effects of TLR7/8 agonist on low-dose cyclophosphamide-treated C26 model","presenterFirst":"Lixin","presenterLast":"Li","keywords":"Immunotherapy;Cyclophosphamide;Toll like receptor ligand","target":"TLR7/8","tumor":"colorectal","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"},{"id":3534,"name":3534,"title":"The TLR7/8 agonist R848 induces antitumor responses and attenuates cachexia in a murine model of pancreatic ductal adenocarcinoma","presenterFirst":"Katherine","presenterLast":"Michaelis","keywords":"Cachexia;Immunotherapy;TLR7;Mouse models","target":"TLR7/8","tumor":"pancreatic","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"TLR9","name":"TLR9","presenterLast":"TLR9","children":[{"id":4571,"name":4571,"title":"EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models","presenterFirst":"Barbara","presenterLast":"Volz","keywords":"Immunomodulation;Tumor microenvironment;T cell","target":"TLR9","tumor":"colorectal_lymphoma_melanoma_breast","sage":"target-tumor","pharma":"academia","combo":"no","model":"preclinical xeno"}]},{"id":"TNIK","name":"TNIK","presenterLast":"TNIK","children":[{"id":455,"name":455,"title":"Traf2-and Nck-interacting kinase (TNIK) inhibitor, NCB-0846, suppresses TGF-\u03b21-induced epithelial-mesenchymal transition in lung cancer","presenterFirst":"Teppei","presenterLast":"Sugano","keywords":"EMT;TGF-beta;Metastasis;Therapeutics","target":"TNIK","tumor":"lung","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"}]}]}
